TECH & INNOVATION

BRIM Biotechnology, Inc. and Ora, Inc. Announce New Partnership to Accelerate the Development of Regenerative Peptide Therapy, BRM421 for Dry Eye Syndrome

BRIM Biotechnology, Inc. ("BRIM") a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. ("ORA") the world's leading, ophthalmic research organization, for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM intends to initiate Phase 3 clinical studies with Ora's support later this year.

Recommended Stories

Real Time Analytics